NCT03643861 |
RAD 1802: Pilot Trial of LINAC Based Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI) |
NCT04532177 |
Stereotactic Body Radiation Therapy (SBRT) for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery |
NCT03043794 |
Study of Stereotactic Radiotherapy for Breast Cancer |
NCT02958774 |
Hypofractionated Radiation Therapy for Patients With Breast Cancer Receiving Regional Nodal Irradiation |
NCT04990921 |
Study of Palliative Radiation Combined With Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer |
NCT04360330 |
SABER Study for Selected Early Stage Breast Cancer |
NCT03936478 |
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer |
NCT04040569 |
A Phase I Dose Escalation Study of Single Fraction Pre-operative Stereotactic Partial Breast Irradiation (S-PBI) for Early Stage Breast Cancer |
NCT05412225 |
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer |
NCT02977468 |
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer |
NCT03460067 |
Omission of Radiation in Patients With Her-2 Positive Breast Cancer |
NCT04454528 |
BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy |
NCT04690855 |
A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer |
NCT04837209 |
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer |
NCT04756505 |
Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial |
NCT04648904 |
Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer |
NCT03345420 |
Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer |
NCT03945721 |
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients |
NCT04849871 |
Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma |
NCT04923542 |
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases |
NCT04895761 |
Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer |
NCT04965688 |
Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition |
NCT02515110 |
Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer |
NCT04234386 |
GammaPod Dose Escalation Radiation for Early Stage Breast Cancer |
NCT02927912 |
Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction |
NCT03909282 |
Phase 2 Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma |
NCT02400658 |
Efficacy of IORT With CT-Guided HDR Brachytherapy for Treatment of Breast Cancer |
NCT04888975 |
A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients With Breast Cancer Related Lymphedema (BCRL) After Lymphatic Surgery |
NCT03789097 |
Vaccination With Flt3L, Radiation, and Poly-ICLC |
NCT03916068 |
Acute Post-Radiation Hyperbaric Oxygen (HBO2) for Breast Cancer Patients Who Have Recently Completed Radiation Therapy |
NCT04443413 |
Assessing the Rate of Complications in X-Ray Therapy Versus Proton Beam Radiation Therapy After Breast Conserving Surgery or Mastectomy in Treating Patients With Breast Cancer |
NCT02956473 |
Supine MRI in Breast Cancer Patients Undergoing Upfront Surgery or Receiving Neoadjuvant Therapy |
NCT05289466 |
Oncoplastic Partial Mastectomy With Intraoperative Radiation Therapy (IORT) in Early Stage Breast Cancer Patients With Prior History of Chest Wall Radiation. |
NCT01245712 |
Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer |
NCT05245812 |
Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy |
NCT04959474 |
SABR-CaRe in Early Stage Breast Cancer |
NCT04871516 |
Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer |
NCT02917421 |
Accelerated Radiation Therapy (ART) to the Breast and Nodal Stations |
NCT05340673 |
Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer |
NCT04044872 |
Hyperpolarized Carbon 13-Based Metabolic Imaging to Detect Radiation-Induced Cardiotoxicity |
NCT05233696 |
Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC |
NCT04175210 |
Prospective Randomized Study of Accelerated Radiation Therapy (PRART) |
NCT05130801 |
A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery |
NCT03979508 |
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer |
NCT03546686 |
Peri-Operative Ipilimumab+Nivolumab and Cryoablation in Women With Triple-negative Breast Cancer |
NCT02926729 |
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy |
NCT00734838 |
Optical Spectroscopy During Breast Cancer Surgery and Core Needle Biopsy |
NCT03561454 |
An Investigator Initiated Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft® Axxent® eBx System |
NCT03216421 |
Intraoperative Radiation Therapy (IORT) in DCIS |
NCT04770714 |
Prospective Comparison of Breast MRI vs Contrast Mammography Prior to Surgery in Breast Cancer Patients |
NCT03012399 |
Hypnosedation in Relaxing Patients Undergoing Breast Cancer Surgery |
NCT03768492 |
Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy |
NCT04233385 |
Myofascial Massage for Pain and Immobility Following Breast Cancer Surgery |
NCT04272801 |
Neoadjuvant Endocrine Therapy Tolerance in Geriatric Early Stage ER+ Breast Cancer |
NCT03796273 |
Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases |
NCT00625417 |
Optical Spectroscopy in Evaluating Tumor Margins in Patients Who Have Undergone Surgery for Breast Tumors |
NCT01185132 |
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy |
NCT04225585 |
Well-Being After Breast Cancer Surgery |
NCT04373031 |
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer |
NCT05094102 |
Intraoperative Evaluation of Axillary Lymphatics |
NCT03632941 |
A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer |
NCT03564782 |
Examining Bioactivity of PVSRIPO in Invasive Breast Cancer |
NCT04603911 |
RCT Comparing ESPB Solutions in Breast Surgery |
NCT04371913 |
Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study |
NCT02689427 |
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer |
NCT04349111 |
An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite" |
NCT05190770 |
A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer |
NCT03990610 |
An Investigational Surgical Procedure (Vascularized Lymph Node Transfer) in Reducing the Risk of Lymphedema in Patients With Breast Cancer Undergoing Breast Reconstruction |
NCT04815083 |
Fluorescence Imaging of Carcinoma During Breast Conserving Surgery |
NCT03542175 |
A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy |
NCT05351424 |
AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc |
NCT03488693 |
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer |
NCT01901094 |
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy |
NCT04588545 |
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease |
NCT04993313 |
Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study |
NCT03765983 |
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases |
NCT04427293 |
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) |
NCT01766297 |
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer |
NCT04852887 |
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) |
NCT04020575 |
Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*) |
NCT04270149 |
Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer |
NCT03473639 |
A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy |
NCT04139993 |
RBX7455 Before Surgery for the Treatment of Operable Breast Cancer |
NCT05325632 |
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab |
NCT02564848 |
Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Estrogen-Positive Breast Cancer Over Age 65 |
NCT01570998 |
Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery |
NCT02422498 |
Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy |
NCT04563507 |
Combined Immunotherapies in Metastatic ER+ Breast Cancer |
NCT04348747 |
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer |
NCT04329065 |
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer |
NCT05378464 |
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer |
NCT04368702 |
CONFIRM: Magnetic Resonance Guided Radiation Therapy |
NCT03598257 |
Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer |
NCT02755896 |
Trial to Compare Radiation Fibrosis With Five Versus Three Fractions |
NCT04674306 |
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer |
NCT05025020 |
Use of an Interactive 3D Tool During Consultation for Breast Reconstruction Surgery |
NCT05081492 |
CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer |
NCT04998682 |
Prospective Evaluation of Targeted Axillary Dissection (TAD) |
NCT02229084 |
Vaccination of High Risk Breast Cancer Patients |
NCT04683679 |
A Study of Radiation Therapy With Pembrolizumab and Olaparib in Women Who Have Triple-Negative Breast Cancer |
NCT04149522 |
Evaluation of Mepitel Film® in Preventing Epidermitis in Patients Receiving Radiation Therapy for Breast Cancer |
NCT03804944 |
Converting HR+ Breast Cancer Into an Individualized Vaccine |
NCT05113927 |
Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery. |
NCT02912312 |
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer |
NCT04899908 |
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases |
NCT04120246 |
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer |
NCT04946864 |
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer |
NCT04052555 |
Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer |
NCT01928589 |
Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer |
NCT04081389 |
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer |
NCT02938442 |
Vaccination of Triple Negative Breast Cancer Patients |
NCT04440982 |
Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients Receiving Neoadjuvant Therapy |
NCT03801369 |
Olaparib and Durvalumab in Treating Patients With Metastatic Triple Negative Breast Cancer |
NCT02945579 |
Eliminating Surgery or Radiotherapy After Systemic Therapy in Treating Patients With HER2 Positive or Triple Negative Breast Cancer |
NCT05159778 |
Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA) |
NCT02290834 |
Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer |
NCT03012230 |
Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer |
NCT04108858 |
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer |
NCT04521764 |
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer |
NCT02603341 |
Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial |
NCT04443348 |
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) |
NCT04481113 |
Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer |
NCT02411656 |
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy |
NCT05183828 |
Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-II Breast Cancer |
NCT04009044 |
Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast |
NCT03691493 |
Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis |
NCT02204098 |
Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy |
NCT04879849 |
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers |
NCT04389281 |
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma |
NCT04857697 |
Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer |
NCT03077841 |
Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer |
NCT04190056 |
Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer |
NCT03213041 |
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer |
NCT04554316 |
Aesthetic Effect of Steri-Strip Orientation on Healing and Scar Appearance in Breast Surgery |
NCT03955991 |
VSMART (Video-Conference Stress Management and Relaxation Training for Older Women With Breast Cancer) |
NCT03122444 |
Imipramine on ER+ve and Triple Negative Breast Cancer |
NCT04294225 |
Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer |
NCT04711824 |
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases |
NCT04084730 |
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer |
NCT05098210 |
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer |
NCT04330625 |
Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477) |
NCT04568616 |
Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI) |
NCT03694756 |
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer |
NCT03725059 |
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) |
NCT04266249 |
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy |
NCT04777786 |
Early Rehabilitation for Breast Cancer - A Randomized Control Trial |
NCT04003038 |
Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery |
NCT04534010 |
Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts |
NCT04553770 |
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer |
NCT04331067 |
Cabiralizumab in Combination With Nivolumab and Neoadjuvant Chemotherapy in Patients With Localized Triple-negative Breast Cancer |
NCT04606030 |
LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge) |
NCT04636710 |
Refining Local-Regional Therapy for IBC |
NCT04647487 |
A Study of LY3484356 in Women With Breast Cancer Before Having Surgery |
NCT02593175 |
Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC |
NCT03808337 |
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease |
NCT04947917 |
Axillary Lymph Node Tattoo Marking Study |
NCT04445844 |
INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study |
NCT03596073 |
Topical Calcipotriene Treatment for Breast Cancer Immunoprevention |
NCT03980509 |
A "Window Trial" on Curcumin for Invasive Breast Cancer Primary Tumors |
NCT04535323 |
Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer |
NCT05219695 |
Medical Imaging and Thermal Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI) |
NCT05177796 |
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer |
NCT03572374 |
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job |
NCT03237572 |
Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer |
NCT03272334 |
Her2-BATS and Pembrolizumab in Metastatic Breast Cancer |
NCT03820141 |
Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer |
NCT03220893 |
Molecular Breast Imaging and Digital Breast Tomosynthesis in Screening Patients With Dense Breast Tissue |
NCT03379428 |
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer |
NCT05333874 |
CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage |
NCT03573648 |
Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer |
NCT05319873 |
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer |
NCT03822312 |
A Pilot Study of Tomographic Optical Breast Imaging (DBT-TOBI) to Monitor Response to Neoadjuvant Therapy |
NCT04054752 |
Vaccine Response With NT-I7 |
NCT04784715 |
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) |
NCT04294628 |
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer |
NCT03696030 |
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases |
NCT04265872 |
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC |
NCT03742102 |
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer |
NCT04556773 |
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer |
NCT04197687 |
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery |
NCT04538742 |
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer |
NCT03923504 |
Improving Exercise Capacity With Tailored Physical Activity in Lymphoma & Breast Cancer Patients Undergoing Tx |
NCT04090398 |
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones |
NCT03095352 |
Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease |
NCT04824027 |
Breast Elasticity Imaging During Neoadjuvant Chemotherapy |
NCT04986579 |
Scalp Cooling in MBC |
NCT05313191 |
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors |
NCT03620201 |
M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer |
NCT03292198 |
Subclinical Lymphedema Treatment Study |
NCT05054374 |
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer |
NCT03796559 |
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes |
NCT05130580 |
Patient-Specific Decision Aid System for Shared Decision Making About Breast Reconstruction |
NCT03449238 |
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients |
NCT04514484 |
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV |
NCT03168737 |
18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients |
NCT03535506 |
Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery |
NCT02335671 |
Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy |
NCT03179904 |
FASN Inhibitor TVB-2640 and Trastuzumab in Combination With Paclitaxel or Endocrine Therapy for the Treatment of HER2 Positive Metastatic Breast Cancer |
NCT04397185 |
Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer |
NCT03351348 |
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control |
NCT03432741 |
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer |
NCT05163223 |
Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer |
NCT04647916 |
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases |
NCT03747120 |
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab |
NCT03384914 |
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer |
NCT04677816 |
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients |
NCT04072393 |
Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers |
NCT03321045 |
Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness |
NCT03941730 |
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer |
NCT04570722 |
Ipsilateral Peripheral Intravenous Access Procedures (The iPIVAP Study) |
NCT04768426 |
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer |
NCT03554044 |
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer |
NCT04491591 |
Implementing BREASTChoice Into Practice |
NCT04692831 |
Testing a New Imaging Agent to Identify Cancer |
NCT04147494 |
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues |
NCT03428802 |
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability |
NCT04282044 |
Study of CRX100 in Patients With Advanced Solid Tumors |
NCT04215146 |
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study |
NCT03739931 |
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies |
NCT03960463 |
EO2 Oxygen Delivery To Study Success Rate of Surgically Closed Wounds |
NCT03504488 |
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) |
NCT05203445 |
A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer |
NCT05076760 |
Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC) |
NCT03303846 |
Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients |
NCT01376505 |
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors |
NCT05144698 |
RAPA-201 Therapy of Solid Tumors |
NCT05064085 |
Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer |
NCT04144023 |
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ |
NCT03567720 |
Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC |
NCT04673448 |
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer |
NCT04039230 |
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. |
NCT05094804 |
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With a PD-1 Inhibitor |
NCT03025035 |
Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer |
NCT04650256 |
Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences |
NCT04958785 |
Study to Evaluate the Safety and Efficacy of Magrolimab Combination Therapy in Adults With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer |
NCT05112536 |
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer |
NCT04891068 |
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer |
NCT05261269 |
A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer |
NCT03202316 |
Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer |
NCT04602117 |
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer |
NCT04134884 |
Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer |
NCT03562637 |
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC |
NCT04333706 |
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) |
NCT03878524 |
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial |
NCT02401347 |
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors |
NCT05269381 |
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study |
NCT04549571 |
Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions |
NCT05069038 |
Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy |
NCT04588246 |
Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery |
NCT03075072 |
Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial |
NCT04787042 |
Phase 1a and Phase 2 Study for PK, PD, Safety and Preliminary Efficacy of ST-067 |
NCT04315233 |
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics |
NCT03328026 |
Combination Study of SV-BR-1-GM in Combination With INCMGA00012 and Epacadostat |
NCT03152929 |
Paravertebral Block Versus Pectoral Nerve Block |
NCT04244552 |
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies |
NCT02531932 |
Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer |
NCT04230941 |
Memory and Attention Adaptation Training-Geriatrics (MAAT-G) |
NCT03549000 |
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. |
NCT03990896 |
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial |
NCT03964532 |
TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer |
NCT04699630 |
A Study of U3-1402 in Subjects With Metastatic Breast Cancer |
NCT05183126 |
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer |
NCT04090567 |
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer |
NCT05029999 |
CD40 Agonist, Flt3 Ligand, and Chemotherapy in Triple Negative Breast Cancer |
NCT04739761 |
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer |
NCT03742245 |
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer |
NCT04243616 |
Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer |
NCT02999477 |
A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer |
NCT04208178 |
Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation |
NCT05020574 |
Microbiome and Association With Implant Infections |
NCT02778685 |
Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer |
NCT04669301 |
Memory and Attention Adaptation Training-Geriatrics (MAAT-G) Phase II |
NCT03310957 |
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer |
NCT01174121 |
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer |
NCT03012100 |
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer |
NCT05218044 |
Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ |
NCT04714983 |
DNX-2440 for Resectable Colorectal Liver Metastasis |
NCT03125928 |
Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer |
NCT03959891 |
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) |
NCT03740256 |
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors |
NCT05255666 |
Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM) |
NCT03606967 |
Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer |
NCT03579472 |
M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer |
NCT04704661 |
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial |
NCT04896320 |
Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer. |
NCT04129216 |
The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer |
NCT03729596 |
MGC018 With or Without MGA012 in Advanced Solid Tumors |
NCT04468061 |
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC |
NCT04222413 |
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors |
NCT03950570 |
ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer |
NCT04660929 |
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors |
NCT05113251 |
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer |
NCT05092373 |
Tumor Treating Fields Therapy in Combination With Chemotherapy for the Treatment of Advanced Solid Tumors Involving the Abdomen or Thorax |
NCT05382286 |
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer |
NCT05305924 |
Fulvestrant Plus Abemaciclib With or Without Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer |
NCT04796220 |
Focused Ultrasound and Gemcitabine in Breast Cancer |
NCT04841148 |
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer |
NCT05382299 |
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer |
NCT04703920 |
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer |
NCT04352777 |
Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer |
NCT03971409 |
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer |
NCT01969643 |
A Safety Study of SGN-LIV1A in Breast Cancer Patients |
NCT04448886 |
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC |
NCT04457596 |
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial |
NCT04849364 |
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer |
NCT05035836 |
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC) |
NCT03854903 |
WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor |
NCT02993159 |
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast |
NCT04316169 |
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer |
NCT04644068 |
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies |
NCT04256941 |
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study |
NCT04205903 |
Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer |
NCT03589339 |
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy |
NCT03650894 |
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients |
NCT05150652 |
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer |
NCT04102436 |
Non-Viral TCR Gene Therapy |
NCT02830724 |
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers |
NCT04738292 |
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study) |
NCT05095207 |
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer |
NCT05306340 |
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With Exemestane Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) |
NCT04895358 |
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) |
NCT04504331 |
Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer |
NCT04174352 |
FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer |
NCT05239143 |
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors |
NCT02436993 |
Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab |
NCT04722692 |
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ |
NCT04348916 |
Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors |
NCT03435952 |
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT |
NCT05274451 |
A Study to Investigate LYL797 in Adults With Solid Tumors |
NCT02476786 |
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score |
NCT04434040 |
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) |
NCT04711252 |
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease. |
NCT05198843 |
Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body |
NCT04592484 |
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors |
NCT04305236 |
Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer |
NCT03685331 |
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer |
NCT05363605 |
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours |
NCT05041101 |
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer |
NCT05262400 |
Study to Assess the Safety and Tolerability of PF-07220060 in Combination With PF-07104091 in Participants With Breast Cancers or Solid Tumors and to Assess the Safety and Tolerability of PF-07220060 and PF-07104091 in Combination With Endocrine Therapy in Participants With Breast Cancer. |
NCT04650451 |
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors |
NCT05384119 |
Study of TTI-101 in Combination for Participants With Metastatic Hormone Receptor-Positive and Human Epithelial Receptor 2 (HER2)-Negative Breast Cancer |
NCT04494945 |
Identifying and Caring for Individuals With Inherited Cancer Syndrome |
NCT04762979 |
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer |
NCT03604315 |
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF |
NCT03032406 |
CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer |
NCT03962647 |
A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer |
NCT04789668 |
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases |
NCT03621982 |
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors |
NCT04596683 |
Same-Day Discharge After Nipple-sparing Mastectomy or Skin-sparing Mastectomy With Breast Reconstruction |
NCT02276443 |
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative |
NCT04862585 |
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel |
NCT03917381 |
GEN1046 Safety Trial in Patients With Malignant Solid Tumors |
NCT05259696 |
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) |
NCT04542135 |
Sulindac and Breast Density in Women at Risk of Developing Breast Cancer |
NCT04491942 |
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer |
NCT03725436 |
ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors |
NCT02872025 |
Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS) |
NCT04432857 |
AN0025 and Pembrolizumab Combination in Advanced Solid Tumors |
NCT02095184 |
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients |
NCT01351103 |
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands |
NCT04614194 |
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib |
NCT02538484 |
Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects |
NCT02422641 |
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis |
NCT04967976 |
Breast Mesh Used in Two-staged Breast Reconstruction |
NCT03775525 |
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer |
NCT02694809 |
The PROMISE Study: Duavee in Women With DCIS |
NCT05000294 |
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types |
NCT03752398 |
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) |
NCT02484404 |
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... |
NCT05307705 |
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors |
NCT03911973 |
Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers |
NCT03393845 |
Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients |
NCT04025216 |
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers |
NCT04072952 |
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer |
NCT02445391 |
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy |
NCT05132582 |
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer |
NCT04539938 |
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer |
NCT02926911 |
Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS |
NCT03975647 |
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer |
NCT03368729 |
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer |
NCT02738866 |
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor |
NCT03517488 |
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors |
NCT03832855 |
Assessing the Immunogenicity of pING-hHER3FL |
NCT04504669 |
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours |
NCT04964934 |
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) |
NCT03412877 |
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer |
NCT05311618 |
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors |
NCT03344965 |
Olaparib In Metastatic Breast Cancer |
NCT04584255 |
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer |
NCT05277051 |
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors |
NCT04589468 |
Researching the Effect of Exercise on Cancer |
NCT03396445 |
Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) |
NCT03238495 |
Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer |
NCT05082610 |
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab |
NCT04925284 |
Study of XB002 in Subjects With Solid Tumors (JEWEL-101) |
NCT04622319 |
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) |
NCT01042379 |
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer |
NCT03304080 |
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast |
NCT03414658 |
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer |
NCT05085002 |
A Study of Lerociclib in Participants With Advanced Breast Cancer |
NCT04494425 |
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer |
NCT03162627 |
Selumetinib and Olaparib in Solid Tumors |
NCT04915755 |
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease |
NCT05374512 |
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) |
NCT03412643 |
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling |
NCT03498716 |
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer |
NCT05104866 |
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) |
NCT04691375 |
A Study of PY314 in Subjects With Advanced Solid Tumors |
NCT03872388 |
Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy |
NCT03424005 |
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer |
NCT04246671 |
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer |
NCT04873362 |
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy |
NCT04740918 |
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) |
NCT03006172 |
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer |
NCT02755272 |
A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer |
NCT04332653 |
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors |
NCT04893109 |
ATEMPT 2.0: Adjuvant T-DM1 vs TH |
NCT05252390 |
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors |
NCT04567420 |
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer |
NCT04799249 |
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) |
NCT04305496 |
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer |
NCT04862663 |
Capivasertib + Palbociclib + Fulvestrant for HR+/HER2- Advanced Breast Cancer (CAPItello-292). |
NCT03280563 |
A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer |
NCT04906395 |
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer |
NCT04851613 |
Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer |
NCT04916002 |
CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer |
NCT04191499 |
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer |
NCT05090358 |
Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer |
NCT04899349 |
Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant |
NCT02264678 |
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents |
NCT03454451 |
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers |
NCT02206984 |
Endocrine Response in Women With Invasive Lobular Breast Cancer |
NCT04802759 |
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer |
NCT02957968 |
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca |
NCT04251533 |
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss |
NCT04187898 |
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer |
NCT03371017 |
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer |
NCT04024436 |
A Study of TAS-120 in Patients With Metastatic Breast Cancer |
NCT04669587 |
ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study) |
NCT05216432 |
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer |
NCT04569747 |
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer |
NCT02488967 |
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer |
NCT04425018 |
MARGetuximab Or Trastuzumab (MARGOT) |
NCT05065411 |
Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer |
NCT03829501 |
Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer |
NCT04727151 |
TAC T-cells for the Treatment of HER2-positive Solid Tumors |
NCT04188548 |
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer |
NCT04224272 |
A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer |
NCT03997123 |
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC |
NCT05169567 |
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer |
NCT02465060 |
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) |
NCT04975308 |
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
NCT04550494 |
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations |
NCT03939897 |
Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer |
NCT03544723 |
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors. |
NCT03367572 |
Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer |
NCT04586335 |
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. |
NCT03841110 |
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors |
NCT04234113 |
Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors |
NCT03845166 |
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors |
NCT03284957 |
Phase 1 / 2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer |
NCT03616587 |
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. |
NCT04641247 |
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study |
NCT02419495 |
Selinexor With Multiple Standard Chemotherapy or Immunotherapy Regimens in Treating Patients With Advanced Malignancies |
NCT04546009 |
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) |
NCT04991480 |
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors |
NCT03930680 |
Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane |
NCT05215574 |
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors |
NCT05150691 |
A Study of DB-1303 in Advanced/Metastatic Solid Tumors |
NCT04872608 |
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer |
NCT04869943 |
Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer |
NCT02955940 |
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib |
NCT03891953 |
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. |
NCT05128773 |
Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity |
NCT04180371 |
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression |
NCT04143711 |
Study of DF1001 in Patients With Advanced Solid Tumors |
NCT03011684 |
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial |
NCT04042701 |
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer |
NCT04742959 |
Study of TT-00420 Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors |
NCT04659603 |
Tusamitamab Ravtansine in Patients With CEACAM5-positive Advanced Solid Tumors |
NCT05252416 |
(VELA) Study of BLU-222 in Advanced Solid Tumors |
NCT05007106 |
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) |
NCT04726332 |
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) |
NCT03667716 |
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. |
NCT03635632 |
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) |
NCT04243837 |
LYT-100 in Healthy Volunteers and BCRL |
NCT04319757 |
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors |
NCT04771520 |
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors |
NCT04682431 |
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors |
NCT05070247 |
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors |
NCT04913337 |
Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies |
NCT03893955 |
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors |
NCT04140526 |
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC |
NCT05395052 |
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors |
NCT04570956 |
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ |
NCT04553133 |
PF-07104091 as a Single Agent and in Combination Therapy |
NCT04478279 |
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors |
NCT04561362 |
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumors Malignancies |
NCT04606446 |
Study of PF-07248144 in Advanced or Metastatic Solid Tumors |
NCT04247126 |
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors |
NCT05069935 |
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors |
NCT05169437 |
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors |
NCT04557449 |
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors |
NCT03997968 |
A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors |
NCT04579380 |
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations |
NCT03568656 |
Study to Evaluate CCS1477 in Advanced Tumours |
NCT03674567 |
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab |
NCT04485013 |
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers |
NCT03678883 |
9-ING-41 in Patients With Advanced Cancers |
NCT05086692 |
A Beta-only IL-2 ImmunoTherapY (ABILITY) Study |
NCT04300556 |
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types |
NCT02635672 |
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer |
NCT04373564 |
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years |
NCT04278144 |
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors |
NCT04144140 |
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101 |
NCT03595059 |
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors |